EUCTR2013-005575-41-ES进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerability up to 2 years in patients with active ankylosing spondylitis - MEASURE 4
ovartis Farmacéutica, S.A.0 个研究点目标入组 324 人开始时间: 2015年3月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 324
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Moderate to severe AS
- •- Prior radiographic evidence according to the Modified NY Criteria (1984)
- •- Inadequate response to NSAIDs
- •Other protocol-definied inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 304
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Pregnancy or lactation
- •- On-going infectious or malignant process on a chest X-ray or MRI
- •- Previous exposure to IL-17 or IL-17R targeting therapies
- •- Previous exposure to any biological immunomodulating agent excluding TNF antagonists
- •- Previous cell depleting therapy
- •Other protocol-definied exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
Study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjectsstages AJCC v. 8 IIIB (not eligible for definite chemoradiation therapy) or stage IV (metastatic) non-small cell lung cancer (NSCLC)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001547-32-FRovartis Pharma AG627
已完成
3 期
A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerability up to 2 years in patients with active ankylosing spondylitisNL-OMON44029ovartis15
进行中（未招募）
1 期
A phase 2b study to assess the efficacy and safety of OBE2109 in subjects with endometriosis.Treatment of Endometriosis-Associated PainMedDRA version: 20.0Level: SOCClassification code 10038604Term: Reproductive system and breast disordersSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2016-001736-35-PLObsEva SA328
已完成
2 期
A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema type I or IIHereditary Angioedema Type I or IIswelling of tissues10003816NL-OMON48423KalVista Pharmaceuticals Limited15
尚未招募
2 期
A randomized, double-blind, placebo-controlled, phase 2a study of the efficacy, safety, and pharmacokinetics of MLN3897 in patients with rheumatoid arthritis taking methotrexate.arthritischronic joint inflammation1000381610023213NL-OMON30310Millenium Pharmaceuticals6